Economic evaluation of meningococcal vaccines: considerations for the future

Research output: Contribution to journalArticle

Authors

  • Hannah Christensen
  • Pierre Levy
  • Maarten J. Postma
  • David E. Bloom
  • Paolo Landa
  • Oliver Damm
  • David M. Salisbury
  • Javier Diez‑Domingo
  • Adrian K. Towse
  • Paula Lorgelly
  • Koonal K. Shah
  • Karla Hernandez‑Villafuerte
  • Vinny Smith
  • Linda Glennie
  • Claire Wright
  • Laura York
  • Raymond Farkouh

Colleges, School and Institutes

External organisations

  • Meningitis Research Foundation; Bristol UK

Abstract

In 2018, a panel of health economics and meningococcal disease experts convened to review methodologies, frameworks, and decision-making processes for economic evaluations of vaccines, with a focus on evaluation of vaccines targeting invasive meningococcal disease (IMD). The panel discussed vaccine evaluation methods across countries; IMD prevention benefits that are well quantified using current methods, not well quantified, or missing in current cost-effectiveness methodologies; and development of recommendations for future evaluation methods. Consensus was reached on a number of points and
further consideration was deemed necessary for some topics. Experts agreed that the unpredictability of IMD complicates an accurate evaluation of meningococcal vaccine benefits and that vaccine cost-effectiveness evaluations should encompass indirect benefits, both for meningococcal vaccines and vaccines in general. In addition, the panel agreed that transparency in
the vaccine decision-making process is beneficial and should be implemented when possible. Further discussion is required to ascertain: how enhancing consistency of frameworks for evaluating outcomes of vaccine introduction can be improved; reviews of existing tools used to capture quality of life; how indirect costs are considered within models; and whether and how the weighting of quality-adjusted life-years (QALY), application of QALY adjustment factors, or use of altered costeffectiveness thresholds should be used in the economic evaluation of vaccines.

Details

Original languageEnglish
Pages (from-to)1-13
Number of pages13
JournalThe European journal of health economics : HEPAC : health economics in prevention and care
Publication statusPublished - 21 Nov 2019

Keywords

  • Meningitis, Meningococcal, Vaccine, Cost-effectiveness, QALY